Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Change in Acquisitions & Divestments (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Change in Acquisitions & Divestments for 4 consecutive years, with $37.8 million as the latest value for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments fell 21.51% to $37.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $159.5 million through Dec 2025, down 9.77% year-over-year, with the annual reading at $159.5 million for FY2025, 9.77% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $37.8 million at Century Therapeutics, up from $35.9 million in the prior quarter.
  • The five-year high for Change in Acquisitions & Divestments was $110.5 million in Q2 2023, with the low at $29.3 million in Q4 2023.
  • Average Change in Acquisitions & Divestments over 4 years is $55.7 million, with a median of $49.9 million recorded in 2024.
  • The sharpest move saw Change in Acquisitions & Divestments soared 93.17% in 2023, then crashed 72.97% in 2024.
  • Over 4 years, Change in Acquisitions & Divestments stood at $52.3 million in 2022, then plummeted by 44.06% to $29.3 million in 2023, then surged by 64.59% to $48.2 million in 2024, then fell by 21.51% to $37.8 million in 2025.
  • According to Business Quant data, Change in Acquisitions & Divestments over the past three periods came in at $37.8 million, $35.9 million, and $42.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.